fAIM Exon 3 Copy Number Genetic Testing for Feline CKD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools lack effective methods to identify domestic and non-domesticated cats at risk for developing tubulointerstitial fibrosis, a precursor to progressive Chronic Kidney Disease (CKD), which is prevalent in felines and lacks preventive measures.
Innovation Solution
Genetic testing to determine the number of copies of exon 3 in the feline apoptosis inhibitor of macrophages (fAIM) genes, identifying cats prone to tubulointerstitial fibrosis and CKD by distinguishing between 3-domain and 4-domain AIM protein variants, allowing for tailored preventive and therapeutic measures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical markers are used to diagnose kidney disease in cats, then diagnosis can be made, but early detection is impossible and significant functional mass loss has already occurred
Solution Approach 1:
The patent applies preliminary action by performing genetic testing for fAIM exon 3 copies before clinical kidney disease manifests. This allows identification of cats at high risk (4 copies) before any functional loss occurs, enabling preventive measures to be taken in advance rather than waiting for traditional markers to show disease presence
2Ease of operation
If NSAIDs are administered to treat pain and inflammation in cats, then pain management is achieved, but kidney damage and progressive CKD can occur
Solution Approach 1:
The patent applies preliminary anti-action by identifying cats with 4 copies of fAIM exon 3 before NSAID administration. This genetic screening allows veterinarians to take preventive action by avoiding NSAIDs in high-risk cats or selecting alternative pain management strategies, thereby preventing kidney damage before it occurs
Solution Approach 2:
The fAIM genetic test serves as an intermediary that mediates between pain management needs and kidney safety. The genetic information acts as a bridge, allowing selection of appropriate pain management strategies based on individual cat risk profiles, thus reconciling the need for effective pain control with prevention of nephrotoxicity
3Device complexity
If no genetic testing is performed, then diagnostic simplicity is maintained, but preventive measures cannot be implemented for at-risk cats
Solution Approach 1:
The patent incorporates preliminary genetic testing as a simple, non-invasive procedure (cheek swab or blood sample) that can be performed early in a cat's life. This adds minimal complexity to the diagnostic workflow while enabling reliable identification of high-risk cats, allowing preventive measures to be implemented without significantly complicating the overall diagnostic process
Data Source
AI summary
Individualized methods for the prevention and/or treatment of kidney disorders in cats are disclosed. The methods include identifying whether or not a cat is predisposed to developing kidney disorders by determining the total number of copies of Exon 3 in the feline apoptosis inhibitor of macrophages (fAIM) genes of the cat. Cats with at least 3 copies of Exon 3 are considered to be predisposed to kidney disorders to include tubulointerstitial fibrosis and/or Chronic Kidney Disease (CKD) and are provided with individualized kidney sparing therapies. Also disclosed is an in vitro amplification kit for determining the number of copies of Exon 3 in the feline apoptosis inhibitor of macrophages (fAIM) genes in a nucleic acid sample of interest.